{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:15:02Z","timestamp":1792289702703,"version":"4.4.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012524","name":"Nederlandse Federatie van Universitair Medische Centra","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012524","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cardiacep.theclinics.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiac Electrophysiology Clinics"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ccep.2023.04.002","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T16:00:49Z","timestamp":1687276849000},"page":"293-305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Catecholaminergic Polymorphic Ventricular Tachycardia"],"prefix":"10.1016","volume":"15","author":[{"given":"Auke T.","family":"Bergeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur A.M.","family":"Wilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"van der Werf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccep.2023.04.002_bib1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fcvm.2019.00092","article-title":"CPVT: arrhythmogenesis, therapeutic management, and future perspectives. A brief review of the literature","volume":"6","author":"Baltogiannis","year":"2019","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"10.1016\/j.ccep.2023.04.002_bib2","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1161\/CIRCEP.111.962027","article-title":"Catecholaminergic polymorphic ventricular tachycardia","volume":"5","author":"Leenhardt","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"3","key":"10.1016\/j.ccep.2023.04.002_bib3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/hrt.37.3.339","article-title":"Bidirectional tachycardia in a child. A study using His bundle electrography","volume":"37","author":"Reid","year":"1975","journal-title":"Br Heart J"},{"key":"10.1016\/j.ccep.2023.04.002_bib4","first-page":"28","article-title":"Catecholamine-induced severe ventriculae arrhythmias with Adams Stockes syndrome in children: report of four cases","volume":"40","author":"Coumel","year":"1978","journal-title":"Br Heart J"},{"issue":"5","key":"10.1016\/j.ccep.2023.04.002_bib5","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1161\/01.CIR.91.5.1512","article-title":"Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients","volume":"91","author":"Leenhardt","year":"1995","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.ccep.2023.04.002_bib6","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehab687","article-title":"Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death","volume":"43","author":"Walsh","year":"2022","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.ccep.2023.04.002_bib7","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1113\/JP276757","article-title":"Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia","volume":"598","author":"Wleklinski","year":"2020","journal-title":"J\u00a0Physiol"},{"issue":"40","key":"10.1016\/j.ccep.2023.04.002_bib8","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.ccep.2023.04.002_bib9","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1161\/CIRCEP.112.970517","article-title":"Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives","volume":"5","author":"van der Werf","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"18","key":"10.1016\/j.ccep.2023.04.002_bib10","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1161\/CIRCULATIONAHA.108.829267","article-title":"Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia","volume":"119","author":"Hayashi","year":"2009","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ccep.2023.04.002_bib11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1161\/CIRCULATIONAHA.121.056018","article-title":"An International Multicenter Cohort Study on \u03b2-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"145","author":"Peltenburg","year":"2022","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ccep.2023.04.002_bib12","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/jamacardio.2017.1320","article-title":"Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia: a randomized clinical trial","volume":"2","author":"Kannankeril","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10.1016\/j.ccep.2023.04.002_bib13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jacep.2021.02.013","article-title":"Burst exercise testing can unmask arrhythmias in patients with incompletely penetrant catecholaminergic polymorphic ventricular tachycardia","volume":"7","author":"Roston","year":"2021","journal-title":"JACC Clin Electrophysiol"},{"issue":"3","key":"10.1016\/j.ccep.2023.04.002_bib14","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/PCC.0000000000001847","article-title":"Catecholaminergic polymorphic ventricular tachycardia: the cardiac arrest where epinephrine is contraindicated","volume":"20","author":"Bellamy","year":"2019","journal-title":"Pediatr Crit Care Med"},{"issue":"21","key":"10.1016\/j.ccep.2023.04.002_bib15","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1016\/j.jacc.2015.09.042","article-title":"Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 10: the cardiac channelopathies: a scientific statement from the American Heart Association and American College of Cardiology","volume":"66","author":"Ackerman","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ccep.2023.04.002_bib16","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.hrthm.2017.12.020","article-title":"Exercise participation and shared decision-making in patients with inherited channelopathies and cardiomyopathies","volume":"15","author":"Etheridge","year":"2018","journal-title":"Heart Rhythm"},{"issue":"4","key":"10.1016\/j.ccep.2023.04.002_bib17","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.hlc.2019.10.013","article-title":"50 years of catecholaminergic polymorphic ventricular tachycardia (CPVT) - time to explore the dark side of the moon","volume":"29","author":"Pflaumer","year":"2020","journal-title":"Heart Lung Circ"},{"issue":"3","key":"10.1016\/j.ccep.2023.04.002_bib18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jacep.2016.01.020","article-title":"Competitive sports participation in patients with catecholaminergic polymorphic ventricular tachycardia: a single center's early experience","volume":"2","author":"Ostby","year":"2016","journal-title":"JACC Clin Electrophysiol"},{"issue":"11","key":"10.1016\/j.ccep.2023.04.002_bib19","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.hrthm.2021.07.061","article-title":"Evaluation of age at symptom onset, proband status, and sex as predictors of disease severity in pediatric catecholaminergic polymorphic ventricular tachycardia","volume":"18","author":"Kallas","year":"2021","journal-title":"Heart Rhythm"},{"issue":"2","key":"10.1016\/j.ccep.2023.04.002_bib20","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.hrthm.2018.08.025","article-title":"Linking the heart and the brain: neurodevelopmental disorders in patients with catecholaminergic polymorphic ventricular tachycardia","volume":"16","author":"Lieve","year":"2019","journal-title":"Heart Rhythm"},{"issue":"2","key":"10.1016\/j.ccep.2023.04.002_bib21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/europace\/eur277","article-title":"Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments","volume":"14","author":"van der Werf","year":"2012","journal-title":"Europace"},{"issue":"5","key":"10.1016\/j.ccep.2023.04.002_bib22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1161\/CIRCULATIONAHA.121.056018","article-title":"An international multicenter cohort study on \u03b2-blockers for the treatment of symptomatic children with catecholaminergic polymorphic ventricular tachycardia","volume":"145","author":"Peltenburg","year":"2022","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ccep.2023.04.002_bib23","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/jamacardio.2022.0219","article-title":"Outcomes of patients with catecholaminergic polymorphic ventricular tachycardia treated with \u03b2-blockers","volume":"7","author":"Mazzanti","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.ccep.2023.04.002_bib24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.hrthm.2015.09.029","article-title":"Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with \u03b21-selective \u03b2-blockers in patients with catecholaminergic polymorphic ventricular tachycardia","volume":"13","author":"Leren","year":"2016","journal-title":"Heart Rhythm"},{"issue":"3","key":"10.1016\/j.ccep.2023.04.002_bib25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1161\/CIRCEP.114.002217","article-title":"Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry","volume":"8","author":"Roston","year":"2015","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"11","key":"10.1016\/j.ccep.2023.04.002_bib26","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/jmg.2004.028993","article-title":"Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients","volume":"42","author":"Postma","year":"2005","journal-title":"J\u00a0Med Genet"},{"issue":"4","key":"10.1016\/j.ccep.2023.04.002_bib27","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nm.1942","article-title":"Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans","volume":"15","author":"Watanabe","year":"2009","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.ccep.2023.04.002_bib28","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/j.jacc.2011.01.026","article-title":"Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia","volume":"57","author":"van der Werf","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"34","key":"10.1016\/j.ccep.2023.04.002_bib29","doi-asserted-by":"crossref","first-page":"e16961","DOI":"10.1097\/MD.0000000000016961","article-title":"Safety and efficacy of flecainide for patients with catecholaminergic polymorphic ventricular tachycardia: a systematic review and meta-analysis","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine (Baltim)"},{"issue":"3","key":"10.1016\/j.ccep.2023.04.002_bib30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1161\/CIRCRESAHA.120.316819","article-title":"RYR2 channel inhibition is the principal mechanism of flecainide action in CPVT","volume":"128","author":"Kryshtal","year":"2021","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.ccep.2023.04.002_bib31","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.hrthm.2012.12.035","article-title":"Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia","volume":"10","author":"Watanabe","year":"2013","journal-title":"Heart Rhythm"},{"issue":"2","key":"10.1016\/j.ccep.2023.04.002_bib32","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.hrthm.2015.09.027","article-title":"Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of \u03b2-blockade","volume":"13","author":"Padfield","year":"2016","journal-title":"Heart Rhythm"},{"issue":"1","key":"10.1016\/j.ccep.2023.04.002_bib33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003495-199345010-00008","article-title":"A\u00a0reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias","volume":"45","author":"Bryson","year":"1993","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ccep.2023.04.002_bib34","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1161\/CIRCEP.110.959916","article-title":"Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia","volume":"4","author":"Hwang","year":"2011","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"6","key":"10.1016\/j.ccep.2023.04.002_bib35","doi-asserted-by":"crossref","first-page":"e0131179","DOI":"10.1371\/journal.pone.0131179","article-title":"Channel activity of cardiac ryanodine receptors (RyR2) determines potency and efficacy of flecainide and R-propafenone against arrhythmogenic calcium waves in ventricular cardiomyocytes","volume":"10","author":"Savio-Galimberti","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ccep.2023.04.002_bib36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.hrcr.2018.04.003","article-title":"A\u00a035-year effective treatment of catecholaminergic polymorphic ventricular tachycardia with propafenone","volume":"5","author":"Marx","year":"2018","journal-title":"HeartRhythm Case Rep"},{"issue":"2","key":"10.1016\/j.ccep.2023.04.002_bib37","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0006-3495(90)82392-4","article-title":"Direct binding of verapamil to the ryanodine receptor channel of sarcoplasmic reticulum","volume":"58","author":"Valdivia","year":"1990","journal-title":"Biophys J"},{"issue":"2","key":"10.1016\/j.ccep.2023.04.002_bib38","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1046\/j.1540-8167.2005.40516.x","article-title":"Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations","volume":"16","author":"Swan","year":"2005","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"issue":"9","key":"10.1016\/j.ccep.2023.04.002_bib39","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.hrthm.2007.05.017","article-title":"Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia","volume":"4","author":"Rosso","year":"2007","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ccep.2023.04.002_bib40","first-page":"S423","article-title":"Long-term effectiveness of beta blocker and calcium blocker combination therapy in patients with CPVT","volume":"7","author":"Rosso","year":"2010","journal-title":"Heart Rhythm"},{"issue":"1","key":"10.1016\/j.ccep.2023.04.002_bib41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pharmthera.2005.01.005","article-title":"Physiology and pharmacology of the cardiac pacemaker (\"funny\") current","volume":"107","author":"Baruscotti","year":"2005","journal-title":"Pharmacol Ther"},{"issue":"14","key":"10.1016\/j.ccep.2023.04.002_bib42","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.jacc.2017.08.038","article-title":"The clinical use of ivabradine","volume":"70","author":"Koruth","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ccep.2023.04.002_bib43","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/pace.13913","article-title":"Ventricular arrhythmia suppression with ivabradine in a patient with catecholaminergic polymorphic ventricular tachycardia refractory to nadolol, flecainide, and sympathectomy","volume":"43","author":"Kohli","year":"2020","journal-title":"Pacing Clin Electrophysiol"},{"issue":"10","key":"10.1016\/j.ccep.2023.04.002_bib44","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1111\/pace.13446","article-title":"Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia","volume":"41","author":"Vaksmann","year":"2018","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.ccep.2023.04.002_bib45","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3389\/fphar.2019.01566","article-title":"The hyperpolarization-activated cyclic-nucleotide-gated channel blocker ivabradine does not prevent arrhythmias in catecholaminergic polymorphic ventricular tachycardia","volume":"10","author":"Bueno-Levy","year":"2020","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.ccep.2023.04.002_bib46","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.3390\/ijms23084435","article-title":"Therapeutic approaches of ryanodine receptor-associated heart diseases","volume":"23","author":"Szentandr\u00e1ssy","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"Pt 3","key":"10.1016\/j.ccep.2023.04.002_bib47","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1042\/BJ20041336","article-title":"Probing a putative dantrolene-binding site on the cardiac ryanodine receptor","volume":"387","author":"Paul-Pletzer","year":"2005","journal-title":"Biochem J"},{"issue":"3","key":"10.1016\/j.ccep.2023.04.002_bib48","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/emmm.201100194","article-title":"Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia","volume":"4","author":"Jung","year":"2012","journal-title":"EMBO Mol Med"},{"issue":"12","key":"10.1016\/j.ccep.2023.04.002_bib49","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1253\/circj.CJ-10-0680","article-title":"Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S\/+) knock-in mouse model","volume":"74","author":"Kobayashi","year":"2010","journal-title":"Circ J"},{"issue":"5","key":"10.1016\/j.ccep.2023.04.002_bib50","doi-asserted-by":"crossref","first-page":"e0125366","DOI":"10.1371\/journal.pone.0125366","article-title":"Antiarrhythmic effects of dantrolene in patients with catecholaminergic polymorphic ventricular tachycardia and replication of the responses using iPSC models","volume":"10","author":"Penttinen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ccep.2023.04.002_bib51","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ijcard.2016.10.078","article-title":"Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs","volume":"227","author":"Li","year":"2017","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.ccep.2023.04.002_bib52","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.hrthm.2017.12.017","article-title":"EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2","volume":"15","author":"Klipp","year":"2018","journal-title":"Heart Rhythm"},{"issue":"13","key":"10.1016\/j.ccep.2023.04.002_bib53","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.1111\/jcmm.16521","article-title":"Efficacy of RyR2 inhibitor EL20 in induced pluripotent stem cell-derived cardiomyocytes from a patient with catecholaminergic polymorphic ventricular tachycardia","volume":"25","author":"Word","year":"2021","journal-title":"J\u00a0Cell Mol Med"},{"issue":"1","key":"10.1016\/j.ccep.2023.04.002_bib54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/14728222.2020.1708326","article-title":"Targeting pathological leak of ryanodine receptors: preclinical progress and the potential impact on treatments for cardiac arrhythmias and heart failure","volume":"24","author":"Connell","year":"2020","journal-title":"Expert Opin Ther Targets"},{"issue":"19","key":"10.1016\/j.ccep.2023.04.002_bib55","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa0708006","article-title":"Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia","volume":"358","author":"Wilde","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ccep.2023.04.002_bib56","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/CIRCEP.112.971754","article-title":"Videoscopic left cardiac sympathetic denervation for patients with recurrent ventricular fibrillation\/malignant ventricular arrhythmia syndromes besides congenital long-QT syndrome","volume":"5","author":"Coleman","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"25","key":"10.1016\/j.ccep.2023.04.002_bib57","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1161\/CIRCULATIONAHA.115.015731","article-title":"Clinical management of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation","volume":"131","author":"De Ferrari","year":"2015","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ccep.2023.04.002_bib58","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.hrthm.2009.03.024","article-title":"Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery","volume":"6","author":"Collura","year":"2009","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ccep.2023.04.002_bib59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2017.03.020","article-title":"Cardiac sympathetic denervation 100years later: jonnesco would have never believed it","volume":"237","author":"Schwartz","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ccep.2023.04.002_bib60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fcvm.2019.00027","article-title":"Cardiac sympathetic denervation in channelopathies","volume":"6","author":"Dusi","year":"2019","journal-title":"Front Cardiovasc Med"},{"issue":"22","key":"10.1016\/j.ccep.2023.04.002_bib61","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1093\/eurheartj\/ehac134","article-title":"Cardiac sympathetic denervation in the prevention of genetically mediated life-threatening ventricular arrhythmias","volume":"43","author":"Schwartz","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ccep.2023.04.002_bib62","doi-asserted-by":"crossref","first-page":"100598","DOI":"10.1016\/j.cpcardiol.2020.100598","article-title":"Renal sympathetic denervation: a comprehensive review","volume":"46","author":"Akinseye","year":"2021","journal-title":"Curr Probl Cardiol"},{"issue":"5","key":"10.1016\/j.ccep.2023.04.002_bib63","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/pace.14230","article-title":"Renal sympathetic denervation for the treatment of recurrent ventricular arrhythmias-ELECTRAM investigators","volume":"44","author":"Garg","year":"2021","journal-title":"Pacing Clin Electrophysiol"},{"issue":"5","key":"10.1016\/j.ccep.2023.04.002_bib64","first-page":"441","article-title":"Renal sympathetic denervation assisted treatment of electrical storm due to polymorphic ventricular tachycardia in a patient with cathecolaminergic polymorphic ventricular tachycardia","volume":"45","author":"Aksu","year":"2017","journal-title":"Turk Kardiyol Dernegi Arsivi"},{"issue":"3","key":"10.1016\/j.ccep.2023.04.002_bib65","first-page":"245","article-title":"Percutaneous renal sympathetic denervation in catecholaminergic polymorphic ventricular tachycardia","volume":"33","author":"Aksu","year":"2017","journal-title":"J\u00a0Arrhythm"},{"issue":"35","key":"10.1016\/j.ccep.2023.04.002_bib66","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1093\/eurheartj\/ehz309","article-title":"Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest","volume":"40","author":"van der Werf","year":"2019","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.ccep.2023.04.002_bib67","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/j.1540-8167.2008.01211.x","article-title":"Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation","volume":"19","author":"Pizzale","year":"2008","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.ccep.2023.04.002_bib68","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1157\/13093988","article-title":"Arrhythmic storm induced by AICD discharge in a patient with catecholaminergic polymorphic ventricular tachycardia","volume":"59","author":"Palanca","year":"2006","journal-title":"Rev Esp Cardiol"},{"issue":"3","key":"10.1016\/j.ccep.2023.04.002_bib69","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/CIRCEP.113.000170","article-title":"Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate","volume":"6","author":"Miyake","year":"2013","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"1","key":"10.1016\/j.ccep.2023.04.002_bib70","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.hrthm.2013.10.027","article-title":"Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia","volume":"11","author":"Roses-Noguer","year":"2014","journal-title":"Heart Rhythm"},{"issue":"12","key":"10.1016\/j.ccep.2023.04.002_bib71","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.hrthm.2018.06.046","article-title":"Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: a systematic review","volume":"15","author":"Roston","year":"2018","journal-title":"Heart Rhythm"},{"issue":"14","key":"10.1016\/j.ccep.2023.04.002_bib72","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.jacc.2017.10.053","volume":"72","author":"Al-Khatib","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.ccep.2023.04.002_bib73","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1017\/S1047951121003413","article-title":"2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients","volume":"31","author":"Shah","year":"2021","journal-title":"Cardiol Young"},{"issue":"3","key":"10.1016\/j.ccep.2023.04.002_bib74","doi-asserted-by":"crossref","first-page":"e151893","DOI":"10.1172\/jci.insight.151893","article-title":"The Purkinje-myocardial junction is the anatomic origin of ventricular arrhythmia in CPVT","volume":"7","author":"Blackwell","year":"2022","journal-title":"JCI Insight"},{"issue":"9","key":"10.1016\/j.ccep.2023.04.002_bib75","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jacep.2017.04.017","article-title":"Effects of catheter ablation targeting the trigger beats in inherited catecholaminergic polymorphic ventricular tachycardia","volume":"3","author":"Kaneshiro","year":"2017","journal-title":"JACC Clin Electrophysiol"},{"issue":"9","key":"10.1016\/j.ccep.2023.04.002_bib76","doi-asserted-by":"crossref","first-page":"e007118","DOI":"10.1161\/CIRCEP.118.007118","article-title":"Effective use of percutaneous stellate ganglion blockade in patients with electrical storm","volume":"12","author":"Tian","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"10","key":"10.1016\/j.ccep.2023.04.002_bib77","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1253\/circj.71.1606","article-title":"Association of atrial arrhythmia and sinus node dysfunction in patients with catecholaminergic polymorphic ventricular tachycardia","volume":"71","author":"Sumitomo","year":"2007","journal-title":"Circ J"},{"issue":"6","key":"10.1016\/j.ccep.2023.04.002_bib78","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.hrthm.2011.01.048","article-title":"Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia","volume":"8","author":"Sy","year":"2011","journal-title":"Heart Rhythm"},{"issue":"1","key":"10.1016\/j.ccep.2023.04.002_bib79","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jccase.2018.09.004","article-title":"Radiofrequency catheter ablation for drug-refractory atrial tachyarrhythmias in a patient with catecholaminergic polymorphic ventricular tachycardia: a case report","volume":"19","author":"Kawada","year":"2018","journal-title":"J\u00a0Cardiol Cases"},{"issue":"3","key":"10.1016\/j.ccep.2023.04.002_bib80","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jacep.2021.12.001","article-title":"Brugada syndrome","volume":"8","author":"Krahn","year":"2022","journal-title":"JACC Clin Electrophysiol"},{"issue":"1","key":"10.1016\/j.ccep.2023.04.002_bib81","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1124\/mol.108.051490","article-title":"Amitriptyline activates cardiac ryanodine channels and causes spontaneous sarcoplasmic reticulum calcium release","volume":"75","author":"Chopra","year":"2009","journal-title":"Mol Pharmacol"},{"issue":"6","key":"10.1016\/j.ccep.2023.04.002_bib82","first-page":"497","article-title":"A\u00a0clinician's guide for conducting randomized trials in individual patients","volume":"139","author":"Guyatt","year":"1988","journal-title":"CMAJ (Can Med Assoc J)"}],"container-title":["Cardiac Electrophysiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877918223000394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877918223000394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T05:42:52Z","timestamp":1761802972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877918223000394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1877918223000394"],"URL":"https:\/\/doi.org\/10.1016\/j.ccep.2023.04.002","relation":{},"ISSN":["1877-9182"],"issn-type":[{"value":"1877-9182","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Catecholaminergic Polymorphic Ventricular Tachycardia","name":"articletitle","label":"Article Title"},{"value":"Cardiac Electrophysiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccep.2023.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}